Lophora Is A Clinical Stage Biotech Company Focused On Drug Discovery For Central Nervous Systemcnsdisordersfounded In 2020 And Spun Out From The University Of Copenhagenlophora Develops Rapid Acting Therapies For Conditions Such As Treatment Resistant Depressionanxietyptsdeating Disordersand Substance Use Disordersthe Company Has Received Funding From Notable Sourcesincluding The Novo Nordisk Foundation And Innovation Fund Denmark Lophora S Pipeline Features Proprietary Psychedelic Inspired Compounds That Target Serotonin Receptorsits Lead Candidatelph 5Is A Selective Small Molecule Agonist Of The Serotonin 5 Ht2A Receptordesigned For Rapid Efficacy And Improved Safetylph 5 Has Completed Ind Enabling Glp Toxicology Studies And Is Set To Enter Phase I Trials In Early 2025The Company Holds Patents For A Novel Class Of Ligands Aimed At Addressing Unmet Clinical Needs In Cns Treatmentlophora S Leadership Team Combines Expertise In Neuropharmacology And Drug Developmentdriving The Company S Clinical Advancements
No conferences found for this company.
| Company Name | Lophora Aps |
| Country |
Denmark
|
| Address | N/A |
| Telephone | N/A |
| N/A |
